Alk-Abello AS
Company Profile
Business description
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
Contact
Boge Alle 6-8
HorsholmDK-2970
DNKT: +45 45747576
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,812
Stocks News & Analysis
stocks
16 ASX stocks to buy and hold forever, revisited
stocks
This ASX200 reject could be a contrarian buying opportunity
stocks
A 15 step checklist from Buffett's forgotten inspiration
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,982.40 | 121.00 | -1.49% |
| CAC 40 | 7,941.91 | 105.69 | -1.31% |
| DAX 40 | 22,328.77 | 292.18 | -1.29% |
| Dow JONES (US) | 41,433.48 | 478.23 | -1.14% |
| FTSE 100 | 8,495.99 | 104.23 | -1.21% |
| HKSE | 23,721.52 | 60.62 | -0.25% |
| NASDAQ | 17,436.10 | 32.22 | -0.18% |
| Nikkei 225 | 36,898.83 | 105.72 | 0.29% |
| NZX 50 Index | 12,273.83 | 137.14 | -1.10% |
| S&P 500 | 5,572.07 | 42.49 | -0.76% |
| S&P/ASX 200 | 7,763.40 | 126.70 | -1.61% |
| SSE Composite Index | 3,374.08 | 5.75 | -0.17% |